A novel tuberculosis antigen identified from human tuberculosis granulomas

Area of Science:

• Immunology
• Microbiology
• Biochemistry

Background:

• Tuberculosis (TB) remains a global infectious disease caused by Mycobacterium tuberculosis (Mtb).
• Current diagnostic and therapeutic strategies require novel biomarkers for improved clinical outcomes.
• Identification of new Mtb antigens is crucial for advancing TB research and vaccine development.

Purpose of the Study:

• To identify novel Mycobacterium tuberculosis (Mtb) antigens directly from infected lung tissues.
• To characterize the immune responses elicited by identified Mtb peptides.
• To evaluate the potential of a specific peptide, PKAp, as a diagnostic biomarker and vaccine candidate.

Main Methods:

• Purification of chaperone-peptide complexes from TB-infected lungs using free-solution isoelectric focusing.
• High-resolution mass spectrometry (LTQ Orbitrap Velos) for peptide identification.
• In vitro assessment of antigen-specific cellular immune responses, including cytokine secretion, T-cell proliferation, and cytotoxic assays.
• In vivo validation of peptide immunogenicity in a mouse model.

Main Results:

• Six Mtb-specific peptides were identified exclusively in TB lung samples.
• A 34-amino acid peptide, PKAp (serine/threonine-protein kinase), induced significant Mtb-specific cellular immune responses in vitro.
• PKAp triggered elevated IFN-γ secretion, CD8(+) T-cell proliferation, and cytotoxic lymphocyte (CTL) responses.
• In vivo studies confirmed PKAp's ability to induce cellular IFN-γ in mice without causing immunopathogenesis.

Conclusions:

• Novel functional Mtb antigens were identified directly from human TB granulomatous lesions.
• PKAp demonstrated significant antigen-specific IFN-γ secretion and a marked cytotoxic lymphocyte response.
• PKAp holds promise as a novel antigen biomarker for the development of effective tuberculosis vaccines.